Correlation Between Humacyte and EFFECTOR Therapeutics
Can any of the company-specific risk be diversified away by investing in both Humacyte and EFFECTOR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Humacyte and EFFECTOR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Humacyte and EFFECTOR Therapeutics, you can compare the effects of market volatilities on Humacyte and EFFECTOR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Humacyte with a short position of EFFECTOR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Humacyte and EFFECTOR Therapeutics.
Diversification Opportunities for Humacyte and EFFECTOR Therapeutics
0.55 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Humacyte and EFFECTOR is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Humacyte and EFFECTOR Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EFFECTOR Therapeutics and Humacyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Humacyte are associated (or correlated) with EFFECTOR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EFFECTOR Therapeutics has no effect on the direction of Humacyte i.e., Humacyte and EFFECTOR Therapeutics go up and down completely randomly.
Pair Corralation between Humacyte and EFFECTOR Therapeutics
Given the investment horizon of 90 days Humacyte is expected to under-perform the EFFECTOR Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Humacyte is 8.55 times less risky than EFFECTOR Therapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The EFFECTOR Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 3.94 in EFFECTOR Therapeutics on August 25, 2024 and sell it today you would lose (3.84) from holding EFFECTOR Therapeutics or give up 97.46% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 14.96% |
| Values | Daily Returns |
Humacyte vs. EFFECTOR Therapeutics
Performance |
| Timeline |
| Humacyte |
| EFFECTOR Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Humacyte and EFFECTOR Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Humacyte and EFFECTOR Therapeutics
The main advantage of trading using opposite Humacyte and EFFECTOR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Humacyte position performs unexpectedly, EFFECTOR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EFFECTOR Therapeutics will offset losses from the drop in EFFECTOR Therapeutics' long position.| Humacyte vs. Crinetics Pharmaceuticals | Humacyte vs. Viridian Therapeutics | Humacyte vs. Cytokinetics | Humacyte vs. Structure Therapeutics American |
| EFFECTOR Therapeutics vs. Celularity | EFFECTOR Therapeutics vs. Humacyte | EFFECTOR Therapeutics vs. NRx Pharmaceuticals | EFFECTOR Therapeutics vs. Reviva Pharmaceuticals Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Complementary Tools
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |